Isaac Bentwich | Source | Co-founder and CEO at Quris-AI

IB

Isaac Bentwich

Co-founder and CEO at Quris-AI
On the record
Represented by:
Share profile 
Link:
Bio
Edit

Isaac is the Founder and CEO of Quris. Prior to Quris, Isaac founded and led three bio-AI technology companies, each of which led revolutions in medicine, genomics, agriculture and conservation. Isaac is a physician and entrepreneur with a passion for leading interdisciplinary teams of scientists and technologists to tackle impactful challenges in the intersection between machine-learning and life-sciences; and to leverage and commercialize the resulting solutions. One of the companies that he founded was Rosetta Genomics (NASDAQ:ROSG), which analyzed the human genome. Isaac led the team at Rosetta Genomics in the discovery of hundreds of novel genes, more so than all the universities in the world combined, and delivered novel cancer diagnostics based on these genes. Its subsidiary, Rosetta Green (TASE:RSTG), was acquired by Monsanto for $35M. Under Isaac’s leadership, team members at Rosetta went on to lead artificial intelligence at IBM, Google and Microsoft. Now, at Quris, Isaac and his team are using a similar bio-AI approach to disrupt the drug development process.

Employment
Sign up to view all
Media
Sign up to view all
Story Ideas
Sign up to view all
  • 2025 Clinical Trials: Overcoming Barriers to Animal-Free Testing
    Isaac highlights the need for "validation of alternative methods," academic incentives, and animal-free materials. He emphasizes collaboration with regulatory bodies and the role of AI and organ-on-chip technologies. By addressing these barriers, the industry can accelerate the transition to ethical and efficient drug discovery.
Recent Quotes
Sign up to view all

  • Thanks to technology breakthroughs, we can confirm the viability and safety of drug candidates well before they reach the clinical testing phase, reducing unnecessary risks and focusing resources, time, and budget on the drugs with the most potential. In our mission to get safe, effective drugs to patients faster, we are working hand-in-hand with leaders across the global pharmaceutical industry to drive the next era of AI-based drug discovery, development, and safety.

  • Thanks to technology breakthroughs, we can confirm the viability and safety of drug candidates well before they reach the clinical testing phase, reducing unnecessary risks and focusing resources, time, and budget on the drugs with the most potential. In our mission to get safe, effective drugs to patients faster, we are working hand-in-hand with leaders across the global pharmaceutical industry to drive the next era of AI-based drug discovery, development, and safety.

  • Thanks to technology breakthroughs, we can confirm the viability and safety of drug candidates well before they reach the clinical testing phase, reducing unnecessary risks and focusing resources, time, and budget on the drugs with the most potential. In our mission to get safe, effective drugs to patients faster, we are working hand-in-hand with leaders across the global pharmaceutical industry to drive the next era of AI-based drug discovery, development, and safety.

Popularity
Sign up to view